NRD
LYEL icon

Nebula Research & Development’s Lyell Immunopharma LYEL Stock Holding History

Nebula Research & Development’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-615
Closed -$39.1K – 584
2023
Q2 		$39.1K Buy
+615
New +$34K 0.03% 322

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return

Nebula Research & Development's LYEL Position: Q3 2023 in Review

Nebula Research & Development sold out of Lyell Immunopharma (LYEL) in Q3 2023, closing a stake of 615 shares — an estimated $39.1K sold.

Nebula Research & Development first reported a position in LYEL in Q2 2023 and held it in 1 quarter. The position peaked at $39.1K in Q2 2023. 106 funds tracked by Wall St. Rank hold LYEL as of Q3 2023.

  • Nebula Research & Development reported no remaining Lyell Immunopharma position as of Q3 2023 after selling out during the quarter.
  • Nebula Research & Development sold 615 Lyell Immunopharma shares in Q3 2023, an estimated $39.1K.
  • Nebula Research & Development first reported a position in Lyell Immunopharma in Q2 2023 and held it in 1 quarter.
  • Nebula Research & Development's Lyell Immunopharma position peaked at $39.1K in Q2 2023.
  • 106 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2023.

Based on Nebula Research & Development's 13F filing for Q3 2023, filed 14 Nov 2023.